Research programme: DprE1 inhibitor therapeutics - UniQuest

Drug Profile

Research programme: DprE1 inhibitor therapeutics - UniQuest

Alternative Names: BTZ043

Latest Information Update: 04 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Queensland
  • Developer UniQuest; University of Queensland
  • Class Benzothiadiazines; Small molecules
  • Mechanism of Action Oxidoreductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Tuberculosis

Most Recent Events

  • 04 Aug 2016 Research programme: DprE1 inhibitor therapeutics - UniQuest is available for licensing -https://www.nlm.nih.gov/cgi/mesh/2013/MB_cgi?mode=&index=245645&field=all&HM=&II=&PA=&form=&input=
  • 04 Aug 2016 Preclinical trials in Tuberculosis in Australia (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top